Centessa Pharmaceuticals (CNTA) Competitors

$39.60 +0.02 (+0.05%)

Closing price 04:00 PM Eastern

Extended Trading

$39.60 -0.01 (-0.01%)

As of 05:41 PM Eastern

CNTA vs. ROIV, MRNA, VTRS, GMAB, and ASND

Should you buy Centessa Pharmaceuticals stock or one of its competitors? MarketBeat compares Centessa Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Centessa Pharmaceuticals include Roivant Sciences (ROIV), Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

How does Centessa Pharmaceuticals compare to Roivant Sciences?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Centessa Pharmaceuticals presently has a consensus target price of $40.70, suggesting a potential upside of 2.78%. Roivant Sciences has a consensus target price of $30.55, suggesting a potential upside of 3.56%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Roivant Sciences is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Roivant Sciences has higher revenue and earnings than Centessa Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	393.97	-$197.53M	-$1.79	N/A
Roivant Sciences	$29.05M	726.79	-$171.98M	-$1.17	N/A

Centessa Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Roivant Sciences' net margin of -6,079.94%. Roivant Sciences' return on equity of -19.04% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Roivant Sciences	-6,079.94%	-19.04%	-18.15%

In the previous week, Roivant Sciences had 3 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 8 mentions for Roivant Sciences and 5 mentions for Centessa Pharmaceuticals. Roivant Sciences' average media sentiment score of 0.76 beat Centessa Pharmaceuticals' score of 0.41 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Roivant Sciences beats Centessa Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to Moderna?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Moderna	-143.55%	-26.64%	-19.32%

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Centessa Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Centessa Pharmaceuticals has higher earnings, but lower revenue than Moderna. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	393.97	-$197.53M	-$1.79	N/A
Moderna	$2.20B	9.01	-$2.82B	-$8.15	N/A

Centessa Pharmaceuticals presently has a consensus target price of $40.70, suggesting a potential upside of 2.78%. Moderna has a consensus target price of $35.73, suggesting a potential downside of 28.58%. Given Centessa Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Centessa Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

In the previous week, Moderna had 28 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 33 mentions for Moderna and 5 mentions for Centessa Pharmaceuticals. Moderna's average media sentiment score of 0.65 beat Centessa Pharmaceuticals' score of 0.41 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	19 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Centessa Pharmaceuticals beats Moderna on 9 of the 16 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to Viatris?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Viatris	-2.04%	19.04%	7.62%

Centessa Pharmaceuticals has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	393.97	-$197.53M	-$1.79	N/A
Viatris	$14.56B	1.38	-$3.51B	-$0.26	N/A

Centessa Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Viatris has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Centessa Pharmaceuticals presently has a consensus target price of $40.70, suggesting a potential upside of 2.78%. Viatris has a consensus target price of $15.71, suggesting a potential downside of 8.96%. Given Centessa Pharmaceuticals' higher possible upside, analysts clearly believe Centessa Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Viatris had 10 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 15 mentions for Viatris and 5 mentions for Centessa Pharmaceuticals. Viatris' average media sentiment score of 0.64 beat Centessa Pharmaceuticals' score of 0.41 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	2 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Centessa Pharmaceuticals beats Viatris on 8 of the 15 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

In the previous week, Genmab A/S had 4 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 9 mentions for Genmab A/S and 5 mentions for Centessa Pharmaceuticals. Genmab A/S's average media sentiment score of 0.71 beat Centessa Pharmaceuticals' score of 0.41 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	1 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Centessa Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S currently has a consensus target price of $39.07, suggesting a potential upside of 45.25%. Centessa Pharmaceuticals has a consensus target price of $40.70, suggesting a potential upside of 2.78%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities research analysts clearly believe Genmab A/S is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Genmab A/S has a net margin of 21.05% compared to Centessa Pharmaceuticals' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.51	$963M	$1.32	20.38
Centessa Pharmaceuticals	$15M	393.97	-$197.53M	-$1.79	N/A

Genmab A/S has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Summary

Genmab A/S beats Centessa Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to Ascendis Pharma A/S?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Centessa Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	393.97	-$197.53M	-$1.79	N/A
Ascendis Pharma A/S	$865.78M	17.69	-$258M	$8.67	28.31

Ascendis Pharma A/S has a net margin of 57.87% compared to Centessa Pharmaceuticals' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Centessa Pharmaceuticals currently has a consensus target price of $40.70, suggesting a potential upside of 2.78%. Ascendis Pharma A/S has a consensus target price of $291.50, suggesting a potential upside of 18.74%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95

Centessa Pharmaceuticals has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market.

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 5 mentions for Centessa Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 0.96 beat Centessa Pharmaceuticals' score of 0.41 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Centessa Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

Get Centessa Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTA vs. The Competition

Export

Metric	Centessa Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.91B	$3.04B	$6.29B	$12.46B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-22.12	19.11	20.89	25.59
Price / Sales	393.97	280.24	522.17	62.83
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	12.11	4.35	9.86	6.70
Net Income	-$197.53M	$72.19M	$3.55B	$333.77M
7 Day Performance	-0.03%	-0.62%	-0.32%	0.45%
1 Month Performance	0.03%	0.22%	1.33%	4.06%
1 Year Performance	222.74%	46.24%	41.10%	36.24%

Centessa Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTA Centessa Pharmaceuticals	2.0925 of 5 stars	$39.60 +0.1%	$40.70 +2.8%	+217.7%	$5.91B	$15M	N/A	200
ROIV Roivant Sciences	2.3431 of 5 stars	$28.32 -0.1%	$30.55 +7.9%	+171.6%	$20.27B	$29.05M	N/A	860	Positive News
MRNA Moderna	1.4769 of 5 stars	$46.71 -1.2%	$35.73 -23.5%	+97.8%	$18.45B	$2.20B	N/A	4,700
VTRS Viatris	2.5693 of 5 stars	$15.53 +2.2%	$14.67 -5.6%	+97.6%	$18.08B	$14.30B	N/A	30,000	Earnings Report
GMAB Genmab A/S	4.3078 of 5 stars	$27.53 +1.8%	$39.07 +41.9%	+37.5%	$17.16B	$3.72B	17.76	3,029

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTA) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Centessa Pharmaceuticals (CNTA) Competitors

CNTA vs. ROIV, MRNA, VTRS, GMAB, and ASND

How does Centessa Pharmaceuticals compare to Roivant Sciences?

Summary

How does Centessa Pharmaceuticals compare to Moderna?

Summary

How does Centessa Pharmaceuticals compare to Viatris?

Summary

How does Centessa Pharmaceuticals compare to Genmab A/S?

Summary

How does Centessa Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTA vs. The Competition

Centessa Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Centessa Pharmaceuticals (CNTA) Competitors

CNTA vs. ROIV, MRNA, VTRS, GMAB, and ASND

How does Centessa Pharmaceuticals compare to Roivant Sciences?

Do analysts prefer CNTA or ROIV?

Which has higher earnings and valuation, CNTA or ROIV?

Which has more risk & volatility, CNTA or ROIV?

Do institutionals & insiders have more ownership in CNTA or ROIV?

Is CNTA or ROIV more profitable?

Does the media prefer CNTA or ROIV?

Summary

How does Centessa Pharmaceuticals compare to Moderna?

Is CNTA or MRNA more profitable?

Do insiders and institutionals have more ownership in CNTA or MRNA?

Which has more volatility and risk, CNTA or MRNA?

Which has stronger earnings & valuation, CNTA or MRNA?

Do analysts rate CNTA or MRNA?

Does the media favor CNTA or MRNA?

Summary

How does Centessa Pharmaceuticals compare to Viatris?

Is CNTA or VTRS more profitable?

Which has higher valuation and earnings, CNTA or VTRS?

Which has more risk and volatility, CNTA or VTRS?

Do insiders and institutionals have more ownership in CNTA or VTRS?

Do analysts rate CNTA or VTRS?

Does the media favor CNTA or VTRS?

Summary

How does Centessa Pharmaceuticals compare to Genmab A/S?

Does the media refer more to GMAB or CNTA?

Do analysts prefer GMAB or CNTA?

Is GMAB or CNTA more profitable?

Do institutionals and insiders hold more shares of GMAB or CNTA?

Which has better valuation and earnings, GMAB or CNTA?

Which has more risk and volatility, GMAB or CNTA?

Summary

How does Centessa Pharmaceuticals compare to Ascendis Pharma A/S?

Which has stronger earnings and valuation, CNTA or ASND?

Is CNTA or ASND more profitable?

Do analysts prefer CNTA or ASND?

Which has more volatility & risk, CNTA or ASND?

Do insiders & institutionals hold more shares of CNTA or ASND?

Does the media prefer CNTA or ASND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTA vs. The Competition

Centessa Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools